Peysaf Worthalter, MD
Psychiatry · Miami, FLNPI 1265627608
Payments from drug & device makers
Across 599 payments — averaging $36.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$6K
- Otsuka America Pharmaceutical, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
- plus $6K from 22 others
What the payments were for
- Consulting fees$3,80417%
- Travel & lodging$1,6117%
- Food & beverage$16,47775%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 57 | $5,590 |
| Otsuka America Pharmaceutical, Inc. | 106 | $2,882 |
| Teva Pharmaceuticals USA, Inc. | 47 | $2,178 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 73 | $1,957 |
| AbbVie(2 entities) | 68 | $1,580 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,404 |
| Johnson & Johnson | 25 | $928 |
| Vanda Pharmaceuticals Inc. | 28 | $798 |
| Lundbeck LLC | 34 | $697 |
| E.r. Squibb & Sons, L.L.C. | 10 | $542 |
| Alkermes, Inc. | 20 | $529 |
| Bausch Health US, LLC | 21 | $433 |
| Neurocrine Biosciences, Inc. | 8 | $396 |
| Sunovion Pharmaceuticals Inc. | 18 | $353 |
| Ironshore Pharmaceuticals Inc. | 18 | $349 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $221 |
| Avanir Pharmaceuticals, Inc. | 12 | $221 |
| Axsome Therapeutics, Inc. | 10 | $199 |
| Almatica Pharma LLC | 8 | $159 |
| Neuronetics, Inc. | 4 | $109 |
| Tris Pharma Inc | 5 | $101 |
| Supernus Pharmaceuticals, Inc. | 6 | $95 |
| Eisai Inc. | 3 | $56 |
| Neos Therapeutics, LP | 3 | $52 |
| Acadia Pharmaceuticals Inc | 1 | $32 |
| Shire North American Group Inc | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,919 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 34 | $47,175 |
| TrintellixVortioxetine Hydrobromide | 30 | $31,889 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $20,376 |
| InvegaPaliperidone | 26 | $11,756 |
| XanaxAlprazolam | 12 | $9,331 |
| Aripiprazole | 119 | $7,812 |
| Risperdal ConstaRisperidone Microspheres | 11 | $6,496 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,580 |
| Asenapine Maleate | 12 | $4,551 |
| Bupropion XlBupropion Hcl | 190 | $4,315 |
| Quetiapine Fumarate | 200 | $4,107 |
| Chlorpromazine Hcl | 22 | $4,041 |
| Fluoxetine Hcl | 76 | $3,799 |
| Divalproex Sodium ErDivalproex Sodium | 33 | $3,729 |
| Escitalopram Oxalate | 270 | $3,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,580 | $47,17534 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $221 | $36,46942 claims |
| Alkermes, Inc.Lybalvi | $529 | $20,37612 claims |
| Johnson & JohnsonInvega, Risperdal Consta | $928 | $18,25237 claims |
| Almatica Pharma LLCSertraline Hcl | $159 | $898144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Miami
- Silvia Silva-DulucMiami$11.7M
- Patricia JunqueraMiami$10.8M
- Evelio SosaMiami$6.9M
- Mario CuervoMiami$6.7M
- Emelina ArochaMiami$4.9M
- Maria RodilMiami$4.5M
- Marc AgroninMiami$4M
- Nancy Navarro-GonzalezMiami$2.6M
- Francisco RicartMiami$2.6M
- Durim BozhdarajMiami$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.